The Department for Health and Social Care has asked NICE to conduct an appraisal of Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer.
Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.